-
25-Hydroxycholesterol Drives AMPK-STAT6 Axis in TAM Educatio
2026-04-25
Xiao et al. (2024) reveal a novel mechanism where 25-hydroxycholesterol (25HC) within tumor-associated macrophages (TAMs) activates lysosomal AMPKα via the GPR155-mTORC1 pathway, leading to STAT6-dependent immunosuppression. Targeting this axis reprograms macrophages and enhances anti-tumor immunity, providing a new immunometabolic checkpoint for cancer therapy.
-
FITC-Concanavalin A (ConA) Conjugate: Technical Use Guide
2026-04-24
FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces, supporting precise workflows in immunofluorescence staining, flow cytometry, and glycobiology research. It should only be used for carbohydrate-binding detection within its defined stability window and is not recommended for non-specific or cross-domain applications.
-
Live-Dead Cell Staining Kit: Practical Protocols and QC Guid
2026-04-24
The Live-Dead Cell Staining Kit enables reliable discrimination between viable and non-viable cultured cells using Calcein-AM and Propidium Iodide dual staining. It is best suited for fluorescence-based cell viability assays in microscopy and flow cytometry workflows, but should not be used for diagnostic or clinical applications.
-
Hepatic sEH-Nrf2 Axis: A New Mechanism in Osteoclastogenesis
2026-04-23
The referenced study uncovers a previously unrecognized liver-bone axis in osteoporosis, demonstrating that hepatic soluble epoxide hydrolase (sEH) drives osteoclast differentiation by suppressing the Nrf2 signaling pathway. These findings suggest that targeting sEH and epoxyeicosatrienoic acids metabolism could open new avenues for chronic inflammation research and bone disease intervention.
-
Ceruletide in Pancreatic Function Research: Protocols & Pitf
2026-04-23
Ceruletide (Caerulein) is the synthetic decapeptide of choice for precise modeling of pancreatic and gastrointestinal physiology. This guide details advanced workflows, troubleshooting tactics, and pivotal innovations—empowering researchers to bridge recent MFGE8-ANXA1-SMAD2/3 axis discoveries into robust, reproducible assays.
-
Murine RNase Inhibitor: Precision RNA Protection in Bone Bio
2026-04-22
Explore how the Murine RNase Inhibitor advances RNA degradation prevention in bone tissue research. This article uniquely bridges molecular RNA protection with emerging insights from bone-immune homeostasis studies, positioning the inhibitor as essential for robust, oxidation-resistant assays.
-
Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog for NGF
2026-04-22
Tacalcitol monohydrate, a synthetic analog of vitamin D3, is a potent topical agent that induces nerve growth factor (NGF) in keratinocytes and enhances anticancer activity in colorectal models. This article details its biological mechanisms, evidence benchmarks, and integration into research workflows with strict protocol guidance.
-
Optimizing Sulfonamides for TB: Activity with Reduced CYP 2C
2026-04-21
This study systematically modified sulfonamide derivatives from sulfaphenazole to improve antimycobacterial efficacy against Mycobacterium tuberculosis while minimizing CYP 2C9 inhibition. The findings identify new leads with strong activity and low cytotoxicity, informing safer anti-TB drug design.
-
CDK9 Inhibitor (A3294): Technical Guidance and Workflow Use
2026-04-21
The CDK9 inhibitor (A3294) provides selective inhibition of cyclin dependent kinase 9 for researchers investigating transcription elongation and HIV-1 propagation. It is not suitable for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions. Careful adherence to technical parameters ensures reproducible, non-cytotoxic results.
-
Improving In Vitro Assessment of Cancer Drug Responses
2026-04-20
Schwartz's dissertation critically refines how in vitro assays distinguish between growth inhibition and cell death in cancer drug evaluation. By disentangling these metrics, the study advances the precision of preclinical drug response characterization, informing both assay design and interpretation for translational oncology research.
-
Viral Induction of RIPK3 Degradation Modulates Necroptosis a
2026-04-20
Liu et al. reveal that certain orthopoxviruses encode a viral protein (vIRD) capable of binding host SCF ubiquitin ligase and the necroptosis adaptor RIPK3, targeting RIPK3 for proteasome-mediated degradation. This viral strategy suppresses necroptosis and inflammation, highlighting a critical mechanism of host-pathogen interaction with implications for ubiquitin-proteasome pathway research.
-
Wogonin Modulates Macrophage Polarization to Alleviate Osteo
2026-04-19
This study demonstrates that wogonin regulates macrophage polarization and inflammatory signaling via the LSD1-p65 axis, resulting in alleviation of osteoarthritis in a mouse model. The findings elucidate a specific molecular mechanism underlying wogonin’s anti-inflammatory effects and provide a robust preclinical framework for future therapeutic development.
-
Blocking GCLC Truncation Delays Age-Related Cataract Onset
2026-04-18
Wei et al. (2024) reveal that age-driven truncation of the γ-glutamylcysteine ligase catalytic subunit (GCLC) at aspartate 499 reduces glutathione synthesis in the lens, accelerating cataract formation. Preventing this truncation in a knock-in mouse model preserves glutathione and significantly delays cataract development, highlighting a novel mechanism and target for age-related cataract prevention.
-
Tigecycline: Glycylcycline Antibiotic in Multidrug-Resistant
2026-04-17
Tigecycline, a next-generation glycylcycline antibiotic, enables reliable experimental modeling of multidrug-resistant infections, including CREC and MRSA. This article delivers actionable workflows, troubleshooting tactics, and evidence-based parameterization to empower resistance studies using APExBIO’s validated Tigecycline resource.
-
(-)-Blebbistatin: Precision Non-Muscle Myosin II Inhibitor U
2026-04-16
Unlock advanced cytoskeletal dynamics research with (-)-Blebbistatin, a highly selective non-muscle myosin II inhibitor from APExBIO. Explore optimized workflows, real-world troubleshooting, and data-driven strategies for dissecting actin-myosin interactions in cell mechanics, cardiac contractility, and mechanotransduction.